fbpx

Parkinson's experts in A Coruña

Anticipate Parkinson's

Get out of doubts,
ask for an estimate without obligation

Diagnosis in a single session

We carry out all the tests required by each person (analytical, neuropsychological, etc.) in a single day to reach an accurate diagnosis.

Take care of your health and the health of your loved ones

1

First- and second-generation relatives with family history of Parkinson's disease

2

Persons with cardiovascular and/or cerebrovascular diseases that represent risk factors for Parkinson's disease

3

People who have had mild, moderate or severe traumatic brain injuries are at increased risk of developing Parkinson's disease.

4

General population aged 30 - 35 years and older who want to know their genetic risk profile for Parkinson's disease.

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease, affecting between 1 and 3% of the population over the age of 65 in Western countries. 

 

The main risk factors for developing Parkinson's disease are: (i) Age ( ii ) Presence of family history of the disease ( iii) Continuous exposure to environmental neurotoxic agents, drugs, pesticides. (iv) Genomic defects in various genes distributed throughout the human genome. ( v ) Cerebral microinfarcts. (vi) Epigenetic changes (DNA methylation). (vii ) Traumatic microinjuries. (viii) Sex (affects more men). (ix) Other factors.

 

The medical and scientific team of the International Center for Neurosciences and Genomic Medicine, led by Dr. Cacabelos, has developed a SINGLE PROTOCOL for clinical action for the diagnosis, treatment and prevention of Parkinson's disease.

What does the protocol consist of?

1.

Clinical evaluation

  • Initial patient assessment. 
  • Complete medical examination. 

2.

Testing

- Complete Blood Evaluation.

- Brain Evaluation:

- Morphological: MRI and CT.

- Functional: Topography, Brain Bioelectrical Activity and Transcranial Doppler.

- Full Body Evaluation: Digestive, Bone, Pulmonary Function, Vascular Examination (Arterial and Venous) and Genitourinary System.

- Cardiovascular evaluation.

- Neuropsychological evaluation.

- Genomic Tracing (*):

- Alzheimer's Genetic Panel.  

- Cerebrovascular Disease Genetic Panel.

- Epigenetic Biomarkers: Global Methylation.

- Pharmacogenetics. (Personalised treatment according to your genetics).

- Food Sensitivity Tests.

- Other tests to be determined at the initial medical assessment:

- Neuro - Otorhinolaryngology.

- Neuro - Ophthalmology.

3.

Analysis of results

At the end of the testing day, we obtain a clinical diagnosis that allows us to carry out a personalised preventive and/or therapeutic intervention programme for each patient.

4.

Medical Report

Includes all the tests in the diagnostic process and the treatment guidelines to follow based on the patient's pharmacogenetic profile.

Dr. Ramón Cacabelos

Dr. Ramón Cacabelos is Professor of Genomic Medicine and one of the most distinguished Spanish scientists, with international recognition in the field of Neurosciences, Genomic Medicine and Pharmacogenetics of diseases of the Central Nervous System.

 

He graduated in Medicine and Surgery at the Faculty of Medicine of the University of Oviedo. He forged his professional career in the Department of Psychiatry at the University of Osaka (Japan), where he obtained a Doctorate in Medical Sciences (Internal Medicine and Psychiatry)(D.M.Sci), and has a second Doctorate in Medicine and Surgery (Ph.D.) from the University of Santiago de Compostela, where he was Professor of Psychiatry after his return to Spain.

 

In his long career he has directed hundreds of research projects, collaborating with Asian, European and American scientists; he has more than 2000 publications and 30 books; he is a member of a hundred scientific and medical societies; he is a referee in the best international scientific journals, Editor-in-Chief of more than 20 national and international medical and scientific journals, and editor of the first WorldGuide for Drug Use and Pharmacogenomics and of the firstPharmacoepigenetics treatise.

Leave us your contact information and we will contact you.

Leave us your contact information and we will contact you.